Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2010

View Archived Issues

Merck & Co. claims new HIV integrase inhibitors

Novartis discovers new orexin receptor antagonists

Zydus-Cadila identifies new GPR119 receptor agonists

Miraculins launches ELISA kit to detect PSP94 in urine

CCR5 gene disruption by SB-728 in HSPCs may be new approach to treat HIV/AIDS

Health Canada conditionally approves Tasigna for CML

ISV-303 enters phase I/II trial for postsurgical ocular pain

Takepron approved for additional indication in Japan

Nesina in combination with thiazolidinediones approved in Japan for diabetes

Soligenix receives FDA grant to advance orBec in gastrointestinal GVHD

FCGR2B gene variant is associated with protection from malaria

Daiichi Sankyo claims new ligands of voltage-gated calcium channel subunit alpha2/delta

Baxter acquires exclusive commercial rights to Glassia in U.S. and other countries

Banyu Pharma and Merck & Co. present new PKB inhibitors

Amgen reports pipeline update for second quarter 2010

WHO grants prequalification status to Pfizer's Prevenar 13

Gruenenthal discloses new bradykinin B1 receptor antagonists

Bristol-Myers Squibb offers pipeline update for Q2 2010

Hepatitis E vaccine HEV-239 is safe in phase III trial in healthy adults

AstraZeneca presents new inhibitors of GlyT-1

Perampanel shows promise in phase III trial in epilepsy

Medivir partners with Daewoong to distribute Xerclear in South Korea

Sunitinib/erlotinib improves progression-free survival in NSCLC

Synthetic calcium phosphate ceramics induce osteogenesis in preclinical study

FDA grants orphan drug status for brain cancer product 2B3-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...